Arcutis Biotherapeutics Inc
ARQT
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
235.8% downsideOvervalued by 235.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.68 Billion |
|---|---|
| Enterprise Value | $2.66 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.13 |
| Beta | 1.59 |
| Outstanding Shares | 129,365,000 |
Return
| Return on Equity | -1.25% |
|---|---|
| Return on Assets | -0.52% |
| Return on Invested Capital | 3.31% |
Valuation & Multiples
| P/E Ratio | -1168.42 |
|---|---|
| PEG | 2127.18 |
| Price to Sales | 7.12 |
| Price to Book Ratio | 21.35 |
| Enterprise Value to Revenue | 6.41 |
| Enterprise Value to EBIT | 271.07 |
| Enterprise Value to Net Income | -1121 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2458▲ 10.06% |
|---|---|
| Total Calls | 334,800▼ 40.04% |
| Total Puts | 82,300▲ 1.48% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 103.91%▲ 2.75% |
|---|---|
| Total Invested | $3.11B▼ 16.86% |
| Investors Holding | 275▼ 16.00% |
ESG Score
No data
About Arcutis Biotherapeutics Inc
Relevant Senate Committees
Drives corporate valuations through tax policy, and its control over entitlement spending (Medicare/Medicaid) directly impacts a significant portion of the pharmaceutical market.
Controls federal spending allocations, which directly impacts funding for agencies like the FDA, NIH, and VA healthcare, thereby influencing research grants and government procurement of pharmaceuticals.
Directly regulates the FDA (drug approval is essential for ARQT) and NIH (critical for R&D funding), making it highly influential over the pharmaceutical and biotech sectors.
Directly impacts pharmaceutical companies through oversight of intellectual property (patent protection is vital for pharma) and antitrust enforcement regarding mergers and and competition.